Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Treatment    crawled date : 2020 - 12 - 02    save search

Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera
Published: 2020-12-02 (Crawled : 17:00) - biospace.com/
PTGX | $25.55 -2.15% -2.19% 520K twitter stocktwits trandingview |
Health Technology
| | O: 1.21% H: 0.0% C: -6.23%

food drug treatment fast track fast track designation designation
Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical
Published: 2020-09-25 (Crawled : 16:01) - globenewswire.com
BBI | $2.12 16.04% twitter stocktwits trandingview |
Health Technology
| | O: 10.26% H: 1.74% C: -5.77%

biotech approval treatment
Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Published: 2020-10-06 (Crawled : 16:01) - globenewswire.com
BBI | $2.12 16.04% twitter stocktwits trandingview |
Health Technology
| | O: 2.25% H: 2.2% C: 1.1%

biotech phase 3 treatment
Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration
Published: 2020-12-02 (Crawled : 15:00) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M twitter stocktwits trandingview |
Health Technology
| | O: 0.27% H: 1.26% C: 0.2%

therapy gene therapy macular treatment gene therapies
Update on Remestemcel-L For the Treatment of COVID-19 ARDS and Steroid-Refractory Acute GVHD
Published: 2020-10-29 (Crawled : 14:26) - globenewswire.com
MESO | $5.03 7.25% 6.76% 500K twitter stocktwits trandingview |
Health Technology
| | O: 4.22% H: 1.75% C: 0.37%

covid treatment covid-19
Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA™ (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)
Published: 2020-05-29 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K twitter stocktwits trandingview |
Health Technology
| | O: 2.95% H: 36.92% C: 30.08%

positive acquired treatment chmp lefamulin
XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia
Published: 2020-07-16 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K twitter stocktwits trandingview |
Health Technology
| | O: 15.61% H: 1.74% C: -6.11%

acquired approval treatment lefamulin health
NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)
Published: 2020-07-28 (Crawled : 13:47) - globenewswire.com
NBRV | $1.42 1.39% 720K twitter stocktwits trandingview |
Health Technology
| | O: -1.23% H: 11.87% C: 2.5%

acquired approval treatment lefamulin
Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme
Published: 2020-12-02 (Crawled : 12:01) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M twitter stocktwits trandingview |
Health Technology
| | O: -1.04% H: 3.67% C: 3.29%

treatment glioblastoma
FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19
Published: 2020-12-02 (Crawled : 11:01) - globenewswire.com
MESO | $5.03 7.25% 6.76% 500K twitter stocktwits trandingview |
Health Technology
| | O: 9.19% H: 0.91% C: -4.05%

covid respiratory fda treatment fast track fast track designation syndros granted grant designation
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
Published: 2020-12-02 (Crawled : 11:01) - globenewswire.com
AXSM | $69.69 1.28% 1.26% 400K twitter stocktwits trandingview |
Health Technology
| | O: 0.66% H: 3.28% C: 2.84%

positive results depression positive results trial treatment
BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients
Published: 2020-09-30 (Crawled : 10:18) - globenewswire.com
BCRX | News | $4.59 -0.43% -0.44% 4.1M twitter stocktwits trandingview |
Health Technology
| | O: -1.17% H: 0.79% C: -9.37%

therapy treatment
Gainers vs Losers
56% 44%

Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M twitter stocktwits trandingview |
Health Technology

SINT | $0.0365 59.39% 37.26% 470M twitter stocktwits trandingview |
Health Technology

WISA 4 | $9.19 50.66% 33.7% 65M twitter stocktwits trandingview |
Electronic Technology

EDBL | News | $6.73 47.91% 32.39% 13M twitter stocktwits trandingview |

GCTK | $0.715 36.27% 26.62% 640K twitter stocktwits trandingview |
Manufacturing

TCON | $2.33 36.26% 26.61% 2M twitter stocktwits trandingview |
Health Technology

TIRX | $0.48 6.43% 24.58% 4.8M twitter stocktwits trandingview |

KZIA | $0.38 30.58% 23.42% 300K twitter stocktwits trandingview |
Health Technology

VNDA | News | $5.23 29.14% 22.56% 24M twitter stocktwits trandingview |
Health Technology

ATNF | $1.91 29.05% 22.51% 310K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.